Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zinpentraxin alfa - Roche

Next Previous
Drug Profile

Zinpentraxin alfa - Roche

Alternative Names: PRM-151; recombinant human pentraxin-2 - Roche; RG-6354; rhPentraxin-2; rhPTX 2; rhSAP; RO-7490677

Latest Information Update: 28 Jan 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Promedior
  • Developer Roche
  • Class Anti-inflammatories; Antifibrotics; Eye disorder therapies; Glycoproteins; Hepatoprotectants; Recombinant proteins; Urologics
  • Mechanism of Action Protein replacements; Transforming growth factor beta1 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myelofibrosis; Scars; Idiopathic pulmonary fibrosis
  • New Molecular Entity No

Highest Development Phases

  • Phase II Myelofibrosis; Scars
  • No development reported Crohn's disease; Kidney disorders; Lung disorders; Non-alcoholic steatohepatitis
  • Discontinued Idiopathic pulmonary fibrosis

Most Recent Events

  • 28 Jan 2026 No recent reports of development identified for phase-I development in Crohn's-disease(In volunteers) in USA (IV, Infusion)
  • 21 May 2024 Efficacy and adverse event data from the phase III STARSCAPE trial in Idiopathic pulmonary fibrosis was presented at the 120th International Conference of the American Thoracic Society (ATS-2024)
  • 09 Dec 2023 Zinpentraxin alfa is still in phase II trials for Myelofibrosis in Canada, France, Germany, Israel, Italy, Netherlands, the US and UK

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top